Sagimet Biosciences INC S-1 registration statements
Registration statements, filed ahead of a public offering, with the business description and financials a first-time investor sees.
NASDAQ
Sagimet Biosciences has filed an amendment to its S-1 registration statement for a proposed offering of 9,000,000 shares of Series A common stock.
NASDAQ
Sagimet Biosciences plans to offer 9 million shares of Series A common stock following positive topline results from its FASCINATE-2 Phase 2b clinical trial for NASH treatment.